AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From AFX CNF)
RNS Number:0453U GlaxoSmithKline PLC 29 March 2007 GLAXOSMITHKLINE SUBMITS BIOLOGICS LICENSE APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR CERVARIX(R) New Vaccine Candidate Developed to Protect Against Cervical Cancer - Filing Includes Data from Almost 30,000 Females LONDON, March 29, 2007 - GlaxoSmithKline announced today that the company has submitted a Biologics License Application (BLA) for CERVARIX(R) (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer candidate vaccine, to the U.S. Food and Drug Administration (FDA). If licensed, the vaccine will be indicated for the prevention of cervical cancer and precancerous lesions associated with the most common cancer-causing human papillomavirus types. For this candidate vaccine, GSK selected a novel proprietary adjuvant system called…